Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Deloitte
Cerilliant
Mallinckrodt
Chinese Patent Office
UBS
Queensland Health
Teva
QuintilesIMS
Cipla

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,326,945

« Back to Dashboard

Which drugs does patent 9,326,945 protect, and when does it expire?

Patent 9,326,945 protects ELIQUIS and is included in one NDA.

This patent has thirty-seven patent family members in twenty-six countries.
Summary for Patent: 9,326,945
Title:Apixaban formulations
Abstract: Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
Inventor(s): Patel; Jatin (West Windsor, NJ), Frost; Charles (Yardley, PA), Jia; Jingpin (Belle Mead, NJ), Vemavarapu; Chandra (Hillsborough, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ) Pfizer Inc. (New York, NY)
Application Number:13/579,796
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,326,945

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,326,945

PCT Information
PCT FiledFebruary 24, 2011PCT Application Number:PCT/US2011/025994
PCT Publication Date:September 01, 2011PCT Publication Number: WO2011/106478

International Patents Family Members for US Patent 9,326,945

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 2538925 ➤ Subscribe
European Patent Office 2538925 ➤ Subscribe
European Patent Office 3017811 ➤ Subscribe
European Patent Office 3246021 ➤ Subscribe
European Patent Office 3251660 ➤ Subscribe
European Patent Office 3257500 ➤ Subscribe
Spain 2562279 ➤ Subscribe
Hong Kong 1180248 ➤ Subscribe
Hong Kong 1224216 ➤ Subscribe
Croatia P20160179 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Novartis
Accenture
Citi
Julphar
QuintilesIMS
Boehringer Ingelheim
Cerilliant
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot